Revenue: As of FY2025 Q3, the actual value is USD 0.EPS: As of FY2025 Q3, the actual value is USD -13.16.EBIT: As of FY2025 Q3, the actual value is USD -6.992 M.<h3>Segment Revenue</h3><ul><li>Research &amp; Development Expenses: $1.5 million for the three months ended September 30, 2025, compared to $3.1 million for the same period in 2024, representing a decrease of 50%.</li><li>General and Administrative Expenses: $5.5 million for the three months ended September 30, 2025, compared to $2.7 million for the same period in 2024, representing an increase of 102%.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: $7.1 million for the three months ended September 30, 2025, compared to $6.5 million for the same period in 2024.</li><li>Operating Loss: $7.0 million for the three months ended September 30, 2025, compared to $5.8 million for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $10.9 million for the nine months ended September 30, 2025, compared to - $5.9 million for the same period in 2024.</li><li>Net Cash Used in Investing Activities: - $1.4 million for the nine months ended September 30, 2025, compared to - $0.1 million for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $15.7 million for the nine months ended September 30, 2025, compared to $1.9 million for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Digital Assets: The company held Bitcoin valued at approximately $1.0 million as of September 30, 2025.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: CDT Equity Inc. plans to continue focusing on the development of clinical-stage compounds, particularly those deprioritized by larger pharmaceutical companies, and aims to improve drug properties and extend patent life through advanced co-crystallization and solid-form technologies.</li><li>Non-Core Business: The company is exploring a shift in operations to include digital asset treasury management as a potential strategic alternative for fundraising.</li><li>Priority: The company is prioritizing the pursuit of additional funding through public or private equity or debt financings to support its current business plan.</li></ul>

CDT Equity | 10-Q: FY2025 Q3 Revenue: USD 0